ArticleThe Journal of surgical research2019
Panitumumab-IRDye800CW for Fluorescence-Guided Surgical Resection of Colorectal Cancer.
Article in The Journal of surgical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tumour-targeted fluorescence-guided surgery in gastrointestinal cancer: A systematic review of preclinical and clinical research.Clinical and translational medicine · 2026Pooled it
- Clinical fluorescent contrast agents for image-guided surgery.Fundamental research · 2026Review
- Fluorescence-Guided Surgery in Colorectal Cancer: State-of-the-Art and Translational Perspectives.Current oncology (Toronto, Ont.) · 2026Review
- Investigating probe-receptor interactions and enhancing fluorescence guided surgery with fluorescence lifetime imaging and NF-800 in HER-2 positive esophageal adenocarcinoma.Scientific reports · 2025Article
- Intraoperative fluorescence in solid head and neck cancer: A scoping review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- Impact of Neoadjuvant Treatment on Target Expression in Rectal Cancer for Near-Infrared Tumor Imaging.Cancers · 2025Article
- Frugal engineering-inspired wearable augmented reality goggle system enables fluorescence-guided cancer surgery.Scientific reports · 2024Article
- Indocyanine Green (ICG) and Colorectal Surgery: A Literature Review on Qualitative and Quantitative Methods of Usage.Medicina (Kaunas, Lithuania) · 2023Review
- Screening of an annexin-A2-targeted heptapeptide for pancreatic adenocarcinoma localization.Molecular oncology · 2023Article
- Safety assessment of fluorescently labeled anti-EGFR Nanobodies in healthy dogs.Frontiers in pharmacology · 2023Article
- EGFR-targeted fluorescent imaging using the da Vinci® Firefly™ camera for gallbladder cancer.World journal of surgical oncology · 2022Article
- First Clinical Results of Fluorescence Lifetime-enhanced Tumor Imaging Using Receptor-targeted Fluorescent Probes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Review
- Fundamentals and developments in fluorescence-guided cancer surgery.Nature reviews. Clinical oncology · 2022Review
- Role of near-infrared fluorescence in colorectal surgery.World journal of gastroenterology · 2021Review
- Intraoperative molecular imaging clinical trials: a review of 2020 conference proceedings.Journal of biomedical optics · 2021Review
- A review of tumor-specific fluorescence-guided surgery for colorectal cancer.Surgical oncology · 2021Review
- Nanomedicines for Endometriosis: Lessons Learned from Cancer Research.Small (Weinheim an der Bergstrasse, Germany) · 2021Review
- Safety and Stability of Antibody-Dye Conjugate in Optical Molecular Imaging.Molecular imaging and biology · 2021Article
- Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study.Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFluorescence-guided surgery (FGS) is a rapidly advancing field that may improve outcomes in several cancer types. Although screening has decreased colorectal cancer (CRC) mortality, it remains a common and often fatal malignancy. In this study, we sought to identify an optical imaging agent for the application of FGS technology to CRC.
methodsWe compared a panitumumab-IRDye800CW conjugate to an IgG-IRDye800CW isotype control. Mice were implanted with one of three CRC cell lines (LS174T, Colo205, and SW948) and imaged with open- and closed-filed fluorescence imaging systems. Fluorescent contrast was quantified by calculating the ratio between tumor and background fluorescence. After 10 d, the mice were sacrificed, and their tumors stained for microscopic imaging.
resultsPanitumumab-IRDye800CW produced significantly greater (P < 0.05) fluorescent contrast in all three cell lines. Average tumor to background ratio was 6.00 versus 2.60 for LS174T, 5.78 versus 2.52 for Colo205, and 4.31 versus 1.70 for SW948. A 1-mg tumor fragment produced significantly greater fluorescent contrast in the Colo205 and SW948 cell lines in the panitumumab-IRDye800CW group. Western blotting for epidermal growth factor receptor (EGFR) and a semiquantitative analysis of EGFR expression noted strong expression in all three cell lines; however, EGFR expression did not directly correlate to tumor to background ratio.
conclusionsPanitumumab-IRDye800CW produces significantly greater fluorescent contrast than IgG-IRDye800CW in a murine model of CRC and is a suitable agent for the application of FGS technology to CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.